Armaghane Danesh Bimonthly Journal (Jul 2023)
Study of protective effects of Palm meristem\'s hydroethanolic extract on polycystic ovary syndrome in female Wistar rats induced with estradiol valerate
Abstract
Background and Aim: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of reproductive ages. The treatment of this disease with chemical drugs is associated with various side effects. Some medicinal plants have chemical compounds that can prevent the occurrence or development of this syndrome. The purpose of this study is to investigate the protective effect of hydroethanolic extract of palm meristem (HEPM) in female rats with polycystic ovary syndrome. Methods: In this experimental study, 42 adult female Wistar rats (180-200 g) were randomly divided into 6 groups (n=7): Control group: (injection of 0.25 ml of normal saline subcutaneously, 0.25 ml of normal saline by gavage, daily). Positive control group: (500 mg/kg HEPM as gavage, daily). Estradiol valerate group: (single subcutaneous injection of estradiol valerate, 2 mg/kg in a volume of 0.25 ml of olive oil). Sham group: (single subcutaneous injection 0.25 ml of olive oil).Treatment group 1 (Estradiol valerate 2 mg/kg in a volume of 0.25 ml of olive oil + HEPM 250 mg/kg as gavage, daily).Treatment group 2 (Estradiol valerate 2 mg/kg in a volume of 0.25 ml of olive oil + HEPM 500 mg/kg as gavage, daily). At the end of experiments all animals were anesthetized with ketamin hydrochloride (50mg/kg) and blood samples were collected from inferior vena cava. The blood samples were centrifuged and serums were separated for biochemical and hormonal studies. The testosterone, estradiol, progesterone, FSH & LH of samples were analyzed. All data were statistically analyzed and compared with control group. The p<0.05 was considered as an indicator of significant differences between the data. Finding: After completing the hormonal and histological tests and studies confirmed the occurrence of PCOS. In rats receiving estradiol valerate they showed PCOS. The serum levels of testosterone and estradiol hormones in the rats in witness group (Estradiol valerate) showed a significant increase compared to the control group. Gonadotropins showed a significant decrease in estradiole valrate group. While in treatment groups 1 and 2 that received HEPM, a significant decrease in testosterone and estradiol hormones was seen. Conclusion: The results of this study showed that the HEPM, because of chemichal composition such as phytoestrogens, flavonoids and other antioxidant substances has able to protect ovarian tissue against the occurrence of polycystic ovary syndrome induced with estradiol valerate.
